SymBio Pharmaceuticals Limited announced a private placement of 6,000,000 common shares at an issue price of for the gross proceeds of ¥2,208,000,00 on October 6, 2023. The transaction will include participation from returning investor Evo Fund managed by Evolution Capital Management LLC. The transaction has been approved by the shareholders of the company.

The company will make 1st allocation on November 10, 2023, 2nd allocation on December 20, 2023, 3rd allocation on February 7, 2024, 4th allocation on March 18, 2024 and 5th allocation on April 19, 2024 of 1,200,000 shares each. The company will receive the funding in multiple tranches. The transaction is expected to close on April 19, 2024.